Martin Joe W 4
4 · AMERICAN MEDICAL SYSTEMS HOLDINGS INC · Filed Jun 21, 2011
Insider Transaction Report
Form 4
Martin Joe W
Sr. VP & Gen Mgr - BPH Therapy
Transactions
- Disposition to Issuer
Common Stock
2011-06-17−7,290→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2011-06-17−12,142→ 36,428 totalExercise: $18.46Exp: 2017-02-11→ Common Stock (12,142 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-06-17−65,000→ 0 totalExercise: $11.17Exp: 2016-03-31→ Common Stock (65,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-06-17−36,428→ 0 totalExercise: $18.46Exp: 2017-02-11→ Common Stock (36,428 underlying) - Disposition to Issuer
Common Stock
2011-06-17−3,954→ 7,290 total - Disposition to Issuer
Stock Option (right to buy)
2011-06-17−65,000→ 65,000 totalExercise: $11.17Exp: 2016-03-31→ Common Stock (65,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-06-17−45,770→ 0 totalExercise: $20.05Exp: 2018-02-10→ Common Stock (45,770 underlying)
Footnotes (7)
- [F1]Pursuant to the merger of a wholly-owned subsidiary of Endo Pharmaceutials Holdings Inc. ("Endo") with and into American Medical Systems Holdings, Inc. (the "Merger"), such shares were disposed of in exchange for $118,620 in cash.
- [F2]These restricted shares were assumed by Endo in the Merger in exchange for 5,507 restricted shares of Endo common stock, having a market value of $38.32 per share on the effective date of the Merger. The vesting terms of the new Endo restricted stock grants will remain the same as the vesting terms of the old grants.
- [F3]This option, which vested with respect to 25% of the shares on March 31, 2010 and with respect to the remaining shares, quarterly over the next three years, was canceled with respect to 65,000 shares in the Merger in exchange for a cash payment of $1,223,950 representing the difference between the exercise price of the option and the $30.00 per share price.
- [F4]This option, which vested with respect to 25% of the shares on March 31, 2010 and with respect to the remaining shares, quarterly over the next three years, was assumed by Endo in the Merger and replaced with an option to purchase 49,107 shares of Endo common stock with an exercise price of $14.79 per share.
- [F5]This option, which vested with respect to 25% of the shares on March 31, 2011 and with respect to the remaining shares, quarterly over the next three years, was canceled with respect to 12,142 shares in the Merger in exchange for a cash payment of $140,118.68 representing the difference between the exercise price of the option and the $30.00 per share price.
- [F6]This option, which vested with respect to 25% of the shares on March 31, 2011 and with respect to the remaining shares, quarterly over the next three years, was assumed by Endo in the Merger and replaced with an option to purchase 27,521 shares of Endo common stock with an exercise price of $24.44 per share.
- [F7]This option, which vested with respect to 25% of the shares on March 31, 2012 and with respect to the remaining shares, quarterly over the next three years, was assumed by Endo in the Merger and replaced with an option to purchase 34,579 shares of Endo common stock with an exercise price of $26.54 per share.